aldosterone has been researched along with bay 94-8862 in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Álvarez de la Rosa, D; Gerona-Navarro, G; González-Muñiz, R; Martín-Martínez, M; Pérez-Gordillo, FL; Rodríguez, Y; Zhou, MM | 1 |
| Filippatos, G; Gheorghiade, M; Kim, SY; Kober, L; Kolkhof, P; Krum, H; Nowack, C; Pitt, B; Ponikowski, P; Zannad, F | 1 |
| Amazit, L; Fagart, J; Fay, MR; Hillisch, A; Khan, JA; Kolkhof, P; Lamribet, K; Le Billan, F; Lombès, M; Rafestin-Oblin, ME; Viengchareun, S | 1 |
| Huang, T; Xu, G; Yang, P | 1 |
| Bauersachs, J; Daniel, JM; Dutzmann, J; Haertlé, M; Kolkhof, P; Musmann, RJ; Schäfer, A; Sedding, DG; Sonnenschein, K | 1 |
| Cherney, DZ; Godoy, LC; Lytvyn, Y; Scholtes, RA; van Raalte, DH | 1 |
| Andrikou, I; Dimitriadis, K; Iliakis, P; Kasiakogias, A; Konstantinidis, D; Leontsinis, I; Tousoulis, D; Tsioufis, C | 1 |
| Battaglia, G; Fiorini, F; Granata, A; La Rosa, S; Maccarrone, R; Ocello, A; Randone, S | 1 |
| Carceller, E; Fagart, J; Kolkhof, P; Le Billan, F; Lombès, M; Perrot, J; Travers, S; Viengchareun, S | 1 |
| Patrono, C; Volpe, M | 1 |
| Epstein, M | 1 |
5 review(s) available for aldosterone and bay 94-8862
| Article | Year |
|---|---|
The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges.
Topics: Aldosterone; Diabetic Nephropathies; Drug Therapy, Combination; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines | 2016 |
Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Topics: Adult; Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hyperkalemia; Mineralocorticoid Receptor Antagonists; Naphthyridines; Renin; Renin-Angiotensin System | 2019 |
Future Anti-aldosterone Agents.
Topics: Aldosterone; Drug Development; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines; Renin-Angiotensin System | 2018 |
[Antifibrotic renal role of mineralcorticoid receptor antagonists].
Topics: Aldosterone; Body Fluids; Cardiovascular Diseases; Clinical Trials as Topic; Cytokines; Diabetic Nephropathies; Eplerenone; Fibrosis; Heart; Heart Diseases; Homeostasis; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Naphthyridines; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic; Spironolactone | 2019 |
Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
Topics: Aldosterone; Cardiovascular Diseases; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic | 2021 |
1 trial(s) available for aldosterone and bay 94-8862
| Article | Year |
|---|---|
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Topics: Administration, Oral; Aged; Albuminuria; Aldosterone; Blood Pressure; Cardio-Renal Syndrome; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Male; Mineralocorticoid Receptor Antagonists; Naphthyridines; Natriuretic Peptide, Brain; Peptide Fragments; Potassium | 2013 |
5 other study(ies) available for aldosterone and bay 94-8862
| Article | Year |
|---|---|
Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.
Topics: Amino Acid Sequence; Animals; Benzoxazines; Dihydropyridines; Drug Discovery; Humans; Ligands; Macrolides; Mineralocorticoid Receptor Antagonists; Models, Molecular; Oxazolidinones; Peptides; Pyrazoles; Pyrroles; Receptors, Mineralocorticoid; Structure-Activity Relationship; Sulfonamides | 2017 |
Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
Topics: Active Transport, Cell Nucleus; Aldosterone; Blotting, Western; Cell Line; Cell Nucleus; Chromatin Immunoprecipitation; Dose-Response Relationship, Drug; Down-Regulation; Epithelial Sodium Channels; HEK293 Cells; Humans; Kinetics; Microscopy, Fluorescence; Mutation; Naphthyridines; Nuclear Receptor Coactivator 1; Promoter Regions, Genetic; Protein Binding; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Transcriptional Activation | 2015 |
The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.
Topics: Aldosterone; Animals; Apoptosis; Carotid Arteries; Carotid Artery Injuries; Cell Line; Cell Proliferation; Disease Models, Animal; Human Umbilical Vein Endothelial Cells; Humans; Leukocytes; Male; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Naphthyridines; Neointima; Neovascularization, Physiologic | 2017 |
Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells.
Topics: Aldosterone; Chromatin Immunoprecipitation; Humans; Kidney; Naphthyridines; Real-Time Polymerase Chain Reaction; RNA-Seq; Sequence Analysis, RNA; Spironolactone; Transcriptome | 2021 |
Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems.
Topics: Aldosterone; Diabetes Mellitus, Type 2; Humans; Mineralocorticoid Receptor Antagonists; Naphthyridines; Receptors, Mineralocorticoid; Renal Insufficiency, Chronic | 2021 |